AVAX Technologies, Inc. Share · US0534953056 (OTC) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of AVAX Technologies, Inc.
No Price
Company Profile for AVAX Technologies, Inc. Share
AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company's product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
Company Data
Name AVAX Technologies, Inc.
Company AVAX Technologies, Inc.
Website
https://www.avax-tech.com
Primary Exchange 
UTC
UTC
ISIN US0534953056
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Adele Sommerfeld
Country United States of America
Currency USD
Employees 0,0 T
Address 2000 Hamilton Street, 19130 Philadelphia
IPO Date 1997-05-15
Stock Splits
| Date | Split |
|---|---|
| 15.05.1997 | 1:2 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | AVXT |
More Shares
Investors who hold AVAX Technologies, Inc. also have the following shares in their portfolio:
